After today’s stock market slump, equity indices Sensex and Nifty have fallen 2% towards their all-time lows, and while the market is forecast to correct in the medium term, all quality and well-known stocks are at their 52-week low. have fallen around the level. , As Prices Drop, Buyers Will Buying Opportunities Here Are the 3 Stocks Below 100 which is trading near its 52-week low which investors can watch.
zomato
Zomato shares hit 52-week high 52-week low of 169.00 on November 16, 2021 and 50.05 on May 10, 2022, indicating that the stock is currently trading at a 59 percent discount from its 52-week high. Zomato’s consolidated revenue rose 110.3 per cent to Rs. 4,192 crore in FY22, and 75 per cent in Q4FY22 to Rs. 1,212 crores. Food order and delivery revenue grew 126 per cent in FY22 to Rs. 3,415 crore, while the Gross Order Value (GoV) grew 77 per cent year-on-year to Rs 5,850 crore in Q4FY22. According to brokerage firm Geojit, Zomato has been launched in over 300 new cities in Q4FY22, bringing the total to 1000+ cities, and all the anticipated plastic packaging used in food orders placed through the company Zomato Will recycle more than 100 percent of the The platform, as well as plans to convert the delivery fleet to 100 percent electric by 2030, reduce carbon footprint. The brokerage has claimed that “Zomato’s growth is on track and we see a strong outlook for the company’s future performance given strong order volume growth, healthy levels of new customer engagement, strong penetration, and low cost.” Let us reiterate our BUY rating on the stock with a revised target price of Rs.84 based on 11x FY23E P/Sell.
Marcsons Pharma
Marksens Pharma shares hit 52-week high 52-week low of 97.60 and on June 14, 2021 43.55 on 24 February 2022, indicating that 44.75, the stock is trading at a discount of 54% from its 52-week high and 2.75 percent off its 52-week low. According to the company’s Q4FY22 result highlights, revenue grew 27 per cent year-on-year and 15 per cent quarter-on-quarter to Rs 418 crore, while gross profit margin declined by 673 basis points year-on-year. EBITDA declined by 33% year-on-year but grew 10% in the quarter to INR 63.6 crore, while the company’s operating margin contracted by 1,366 basis points year-on-year and 72 basis points in the quarter fell to 15.2 percent. , The company’s PAT fell 63 per cent year-on-year and 39 per cent quarter-on-quarter to Rs 29.6 crore and the board of directors proposed a final dividend. 0.25 per equity share with a face value of Rs.0.25 each for the financial year ending March 31, 2022.
In its report, brokerage firm Arihant Capital said: “The company is focusing on key regulated markets in the US and UK, with a focus on high-margin soft gels and OTC products. Also, it has a strong balance. The sheet will support inorganic growth through acquisitions, product licenses and capacity expansion of ANDA. Margins were under pressure due to cost inflation in the second half of FY22. However, it is expected to stabilize around current levels. Backward integration We value Marksans Pharma on both the parameters of EV/EBITDA (7x FY24E) and PE valuation at 10x EPS of FY24E and keep our target price at INR 80 per share (earlier TP: INR 86 per share). Accordingly, we maintain our BUY rating on the stock.”
Bank Of Baroda
Bank of Baroda shares hit 52-week high on NSE 52-week low of 122.70 on April 11, 2022 and 72.50 on 23 August 2021, indicating that the stock is trading at a discount of 18% from its 52-week high and 38% above its 52-week low at current levels. 99.95. The stock is trading higher than the 20-day and 200-day moving averages but below the 5-day, 50-day and 100-day moving averages based on the previous trading price. Brokerage firm Edelweiss Broking Ltd has given a buy rating on the stock for a target price of 120 and Bank of Baroda as his pick of the week. The brokerage said that the management has guided for 10-12% credit growth, about 10 bps improvement in net interest margin (NIM) and credit cost of 1.5% for FY13E. Edelweiss has said that BoB is currently trading at a cheaper valuation of about 0.5x the book value on FY24E, while the business outlook has improved.
The views and recommendations given above are those of individual analysts or broking companies and not of Mint.